Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues by Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K

Get full text

Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. by Ruszniewski, P, Ish-Shalom, S, Wymenga, M, O'Toole, D, Arnold, R, Tomassetti, P, Bax, N, Caplin, M, Eriksson, B, Glaser, B, Ducreux, M, Lombard-Bohas, C, de Herder, W, Delle Fave, G, Reed, N, Seitz, J, Van Cutsem, E, Grossman, A, Rougier, P, Schmidt, W, Wiedenmann, B

Guidelines for diagnosis and therapy of MEN type 1 and type 2. by Brandi, M, Gagel, R, Angeli, A, Bilezikian, J, Beck-Peccoz, P, Bordi, C, Conte-Devolx, B, Falchetti, A, Gheri, R, Libroia, A, Lips, C, Lombardi, G, Mannelli, M, Pacini, F, Ponder, B, Raue, F, Skogseid, B, Tamburrano, G, Thakker, R, Thompson, N, Tomassetti, P, Tonelli, F, Wells, SA, Marx, S

Consensus: Guidelines for diagnosis and therapy of MEN type 1 and type 2 by Brandi, M, Gagel, R, Angeli, A, Bilezikian, J, Beck-Peccoz, P, Bordi, C, Conte-Devolx, B, Falchetti, A, Gheri, R, Libroia, A, Lips, C, Lombardi, G, Mannelli, M, Pacini, F, Ponder, B, Raue, F, Skogseid, B, Tamburrano, G, Thakker, R, Thompson, N, Tomassetti, P, Tonelli, F, Wells S A, J, Marx, S